StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Kotak Securities

BUYSun Pharmaceutical Industries Ltd.

byKotak SecuritiesHorizon: 1 year29 Sept 2026via Zee Business (Live)

Entry₹1,853.9Inferred
Target₹2,150
Total upside +15.97%
Stop lossNot given
CMP₹1,853.5Just now
Active-0.02%+16.00%upside left 12 mo left
Follow Kotak Securities for new callsGet alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 13 other Long-term calls on SUNPHARMASee 61 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 29 Sept, 2:36 pm IST
12 supporting3 neutral4 opposing
Supports the BUY call (12)

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · yesterday

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·28 Sept · yesterday

5 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · 6d ago

11 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·21 Sept · 1w ago

Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

NewsGoogle News·20 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (3)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (4)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.